Fenretinide

Fenretinide

SCHEMBL839699

CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 7/20 1.00
ALDH1A1 P00352 7/20 1.00
MAPT P10636 5/20 1.00
HIF1A Q16665 4/20 1.00
CYP3A4 P08684 4/20 1.00
HSD17B10 Q99714 3/20 1.00
MAPK1 P28482 3/20 1.00
BLM P54132 3/20 1.00
LMNA P02545 3/20 1.00
KDM4E B2RXH2 2/20 1.00
MEN1 O00255 2/20 1.00
GMNN O75496 2/20 1.00
ALOX15 P16050 2/20 1.00
NFKB1 P19838 2/20 1.00
MTOR P42345 2/20 1.00
PMP22 Q01453 2/20 1.00
KMT2A Q03164 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP2C19 P33261 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenretinide SCHEMBL4996036 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL13402304 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL9838209 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL19121 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL15703189 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL11704 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL10629371 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL11703 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL4874840 1.00 RBP4 (1.00) RBP4ALDH1A1MAPTHIF1ACYP3A4
Fenretinide SCHEMBL17593790 0.99 RBP4 (0.98) RBP4ALDH1A1MAPTHIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5567702-A TREATING ALOPECIA L'OREAL (FR) 1996-10-22 US claimed
US-5192534-A Composition for inducing and stimulating hair growth and/or retarding its loss, based on pyrimidine derivatives and sunscreens L'OREAL (FR) 1993-03-09 US claimed
EP-0376821-B1 COMPOSITIONS FOR INDUCING AND STIMULATING HAIR GROWTH AND/OR STOP THEIR FALL BASED ON PYRIMIDINE DERIVATIVES AND UV FILTERS L'OREAL (FR) 1992-08-26 EP claimed
US-4323581-A N-(4-HYDROXYPHENYL)-ALL-TRANS-RETINAMIDE JOHNSON & JOHNSON (US) 1982-04-06 US claimed
US-4190594-A ABSORBERS OF ULTRAVIOLET RADIATION JOHNSON & JOHNSON (US) 1980-02-26 US claimed
US-20190117590-A1 Compositions and Methods for Treating Hyperproliferative Disorders TEXAS TECH UNIVERSITY SYSTEM 2019-04-25 US disclosed
EP-2669267-B1 Compositions and methods for treating hyperproliferative disorders TEXAS TECH UNIV (US) 2018-01-10 EP disclosed
EP-1594544-B1 ORAL COMPOSITIONS OF FENRETINIDE HAVING INCREASED BIOAVAILABILITY AND METHODS OF USING THE SAME LOS ANGELES CHILDRENS HOSPITAL (US) 2016-04-06 EP disclosed
EP-1722771-B1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING AN INFLAMMATORY RESPONSE UNIV MCGILL (CA) 2014-04-23 EP disclosed
US-8642658-B2 Treatment of neural diseases or conditions ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2014-02-04 US disclosed
EP-2669267-A1 Compositions and methods for treating hyperproliferative disorders TEXAS TECH UNIVERSITY (US) 2013-12-04 EP disclosed
US-20130217691-A1 Compositions and Methods for Treating Hyperproliferative Disorders TEXAS TECH UNIVERSITY SYSTEM (US) 2013-08-22 US disclosed
US-4190594-A ABSORBERS OF ULTRAVIOLET RADIATION JOHNSON & JOHNSON (US) 1980-02-26 US disclosed
US-4129662-A Retinoic acid derivatives for the treatment of acne JOHNSON & JOHNSON (US) 1978-12-12 US disclosed
US-4126693-A RETINOIC ACID DERIVATIVES IN THE TREATMENT OF ACNE JOHNSON & JOHNSON (US) 1978-11-21 US disclosed
US-4126699-A RETINOIC ACID DERIVATIVES FOR THE TREATMENT OF ACNE JOHNSON & JOHNSON (US) 1978-11-21 US disclosed
US-4126698-A RETINOIC ACID DERIVATIVES IN THE TREATMENT OF ACNE JOHNSON & JOHNSON (US) 1978-11-21 US disclosed
US-4126697-A RETINOIC ACID DERIVATIVES IN THE TREATMENT OF ACNE JOHNSON & JOHNSON (US) 1978-11-21 US disclosed
US-4108880-A ULTRAVIOLET ABSORBERS JOHNSON & JOHNSON (US) 1978-08-22 US disclosed
US-4055659-A Retinoic acid derivatives JOHNSON & JOHNSON (US) 1977-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117590-A1 Compositions and Methods for Treating Hyperproliferative Disorders SGMS1, S1PR1, SPHK1 RBP4 385/4885ALDH1A1 1300/4885MAPT 2661/4885
US-20130217691-A1 Compositions and Methods for Treating Hyperproliferative Disorders SGMS1, S1PR1, SPHK1 RBP4 385/4885ALDH1A1 1300/4885MAPT 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.